$299.81
2.36% day before yesterday
Nasdaq, May 30, 07:45 pm CET
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Alnylam Pharmaceuticals, Inc Stock price

$304.56
+41.32 15.70% 1M
+51.55 20.37% 6M
+69.25 29.43% YTD
+154.53 103.00% 1Y
+176.79 138.37% 3Y
+170.99 128.02% 5Y
+173.35 132.12% 10Y
Nasdaq, Closing price Fri, May 30 2025
+11.66 3.98%
ISIN
US02043Q1076
Symbol
ALNY
Sector
Industry

Key metrics

Market capitalization $39.71b
Enterprise Value $38.10b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.23
P/S ratio (TTM) P/S ratio 16.91
P/B ratio (TTM) P/B ratio 343.82
Revenue growth (TTM) Revenue growth 17.21%
Revenue (TTM) Revenue $2.35b
EBIT (operating result TTM) EBIT $-115.37m
Free Cash Flow (TTM) Free Cash Flow $-75.39m
Cash position $2.63b
EPS (TTM) EPS $-2.09
P/E forward negative
P/S forward 13.72
EV/Sales forward 13.17
Short interest 3.73%
Show more

Is Alnylam Pharmaceuticals, Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Alnylam Pharmaceuticals, Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

35 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

25x Buy
71%
9x Hold
26%
1x Sell
3%

Analyst Opinions

35 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

Buy
71%
Hold
26%
Sell
3%

Financial data from Alnylam Pharmaceuticals, Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,348 2,348
17% 17%
100%
- Direct Costs 328 328
2% 2%
14%
2,020 2,020
20% 20%
86%
- Selling and Administrative Expenses 1,005 1,005
22% 22%
43%
- Research and Development Expense 1,130 1,130
9% 9%
48%
-58 -58
53% 53%
-2%
- Depreciation and Amortization 58 58
8% 8%
2%
EBIT (Operating Income) EBIT -115 -115
34% 34%
-5%
Net Profit -270 -270
19% 19%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Alnylam Pharmaceuticals, Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alnylam Pharmaceuticals, Inc Stock News

Neutral
Business Wire
4 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 9:20 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company's website, ww...
Positive
The Motley Fool
8 days ago
Many investors love the "big mo." That's short for "big momentum.
Neutral
Business Wire
12 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Guided by the theme of “Accepting Challenges to Improve the Health of Humanity,” Alnylam continues to take meaningful steps across each of its six corporate responsibility pillars. This year's edition...
More Alnylam Pharmaceuticals, Inc News

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Head office United States
CEO Yvonne Greenstreet
Employees 2,230
Founded 2002
Website www.alnylam.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today